A Roswell Park Comprehensive Cancer Center team led by Christine Ambrosone and Song Yao has found a distinct molecular signature in the tumor tissues of Black patients with breast cancer.
A growing number of women forgoing reconstruction after a mastectomy say they're satisfied with their choice, even as some did not feel supported by their physician, according to a study led by researchers at the UCLA Jonsson Comprehensive Cancer Center.
Scientists at the UCLA Jonsson Comprehensive Cancer Center describe a new combination therapy that suppresses the MAPK pathway by holding cancer-driving proteins in a death grip.
Postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that has spread to a limited number of lymph nodes, and whose recurrence risk is relatively low, do not benefit from chemotherapy when it is added to hormone therapy, according to initial results from a clinical trial presented at the 2020 San Antonio Breast Cancer Symposium.
University of California, Los Angeles-led research shows that behavioral interventions, mindfulness meditation and survivorship education classes, are effective in reducing depressive symptoms in younger breast cancer survivors, who often experience the highest levels of depression, stress and fatigue that can persist for as long as a decade after their diagnosis.
The American Society of Clinical Oncology issued comprehensive recommendations to guide the cancer community's eventual recovery from the COVID-19 pandemic.
A single protein that appears necessary for the COVID-19 virus to reproduce and spread to other cells is a potential weakness that could be targeted by future therapies.
A cancer-killing virus that City of Hope scientists developed could one day improve the immune system's ability to eradicate tumors in colon cancer patients, according to a study in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.
University of Virginia Cancer Center researchers have identified a gene responsible for the spread of triple-negative breast cancer to other parts of the body, and developed a potential way to stop it.
City of Hope has initiated a phase I clinical trial that will test one of its investigational SARS-CoV-2 vaccines in healthy volunteers between the ages of 18 and 55 who have not had COVID-19.
